Management of familial heterozygous hypercholesterolemia: Position paper of the polish lipid expert forum

Polskie Archiwum Medycyny Wewnetrznej

Volumn 123, Issue 1-2, 2013, Pages 7-10

  Rynkiewicz, Andrzej ^a   Cybulska, Barbara ^b,i   Banach, Maciej ^c   Filipiak, Krzysztof J ^d   Guzik, Tomasz ^e   Idzior Walus, Barbara ^e   Imiela, Jacek ^f   Jankowski, Piotr ^e   Klosiewicz Latoszek, Longina ^b,d   Limon, Janusz ^a   Mysliwiec, Malgorzata ^a   Opolski, Grzegorz ^d   Steciwko, Andrzej ^g   Stepinska, Janina ^h   Zdrojewski, Tomasz ^a  

^a MEDICAL UNIVERSITY OF GDANSK   (Poland)

^b NATIONAL FOOD AND NUTRITION INSTITUTE   (Poland)

^c MEDICAL UNIVERSITY OF LODZ   (Poland)

^d MEDICAL UNIVERSITY OF WARSAW   (Poland)

^e JAGIELLONIAN UNIVERSITY MEDICAL COLLEGE   (Poland)

^f Miedzylesie Specialist Hospital   (Poland)

^g WROCLAW MEDICAL UNIVERSITY   (Poland)

^h INSTITUTE OF CARDIOLOGY   (Poland)

ⁱ Instytut Zywno ci i Zywienia   (Poland)

Author keywords

[No Author keywords available]

Indexed keywords

ANION EXCHANGE RESIN; ANTILIPEMIC AGENT; APOLIPOPROTEIN B; BILE ACID SEQUESTRANT; CHOLESTEROL; COLESEVELAM; EZETIMIBE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; NICOTINIC ACID; ORAL CONTRACEPTIVE AGENT; PROPROTEIN CONVERTASE SUBTILISIN KEXIN TYPE 9; PROTEIN; UNCLASSIFIED DRUG;

AUTOSOMAL DOMINANT INHERITANCE; CARDIOVASCULAR DISEASE; CHOLESTEROL BLOOD LEVEL; CORONARY RISK; FAMILIAL HYPERCHOLESTEROLEMIA; GENE MUTATION; GENETIC SCREENING; HETEROZYGOSITY; HUMAN; ISCHEMIC HEART DISEASE; LIFESTYLE MODIFICATION; MONOTHERAPY; PHENOTYPE; REVIEW;

EID: 84874715089     PISSN: 00323772     EISSN: None     Source Type: Journal    
DOI: 10.20452/pamw.1579     Document Type: Review

References (32)

1. Familial Hypercholesterolemia. A Report of a WHO consultation. WHO, Geneva, Switzerland, 1998.
2. Wierzbicki AS, Humphries SE, Minhas R; Guideline Development Group. Familial hypercholesterolaemia: Summary of NICE guidance. BMJ. 2008; 337: A1095.
3. European Association for Cardiovascular Prevention & Rehabilitation, Reiner Z, Catapano AL, De Backer G, et al.; ESC Committee for Practice Guidelines (CPG) 2008-2010 and 2010-2012 Committees. ESC/EAS Guidelines for the management of dyslipidaemias: The Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS). Eur Heart J. 2011; 32: 1769-1818.
4. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous hypercholesterolemia: A prospective registry study. Eur Heart J. 2008; 29: 2625-2633.
5. Watts GF, Lewis B, Sullivan DR. Familial hypercholesterolemia: A missed opportunity in preventive medicine. Nat Clin Pract Cardiovasc Med. 2007; 4: 404-405.
6. Civeira F; International Panel on Management of Familial Hypercholesterolemia. Guidelines for the diagnosis and management of heterozygous familial hypercholesterolemia. Atherosclerosis. 2004; 173: 55-68.
7. Brown MS, Goldstein JL. How LDL receptors influence cholesterol and atherosclerosis. Sci Am. 1984; 251: 52-60.
8. Innerarity TL, Weisgraber KH, Arnold KS,et al. Familial defective apolipoprotein B-100: Low density lipoproteins with abnormal receptor binding. Proc Natl Acad Sci U S A. 1987; 84: 6919-6923.
9. Abifadel M, Varret M, Rabès JP, et al. Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet. 2003; 34: 154-156.
10. Abifadel M, Rabès JP, Devillers M, et al. Mutations and polymorphisms in the proprotein convertase subtilin kexin 9 (PCSK9) gene in cholesterol metabolism and disease. Hum Mutat. 2009; 30: 520-529.
11. Varret M, Abifadel M, Rabès JP, Boileau C. Genetic heterogeneity of autosomal dominant hypercholesterolemia. Clin Gen. 2008; 78: 1-13.
12. Chmara M, Wasa̧g B, Zuk J, et al. Molecular characterization of Polish patients with familial hypercholesterolemia: Novel and recurrent LDLR mutations. J Appl Genet. 2010; 51: 95-106.
13. Huang CC, Fornage M, Lloyd-Jones DM, et al. Longitudinal association of PCSK9 sequence variations with low-density lipoprotein cholesterol levels: The Coronary Artery Risk Development in Young Adults Study. Circ Cardiovasc Genet. 2009; 2: 354-361.
14. Austin MA, Hutter CM, Zimmern RL, Humphries S. Familial hypercholesterolemia and coronary heart disease: A HuGE association review. Am J Epidemiol. 2004; 160: 421-429.
15. Vermissen J, Oosterveer DM, Yazdanpanach M, et al. Efficacy of statins in familial hypercholesterolemia: A long term cohort study. BMJ. 2008; 337: A2423.
16. Pijlman AH, Huijgen R, Verhagen SN, et al. Evaluation of cholesterol lowering treatment of patients with familial hypercholesterolemia: A large cross-sectional study in The Netherlands. Atherosclerosis. 2010; 209: 189-194.
17. Neil A, Cooper J, Betteridge J, et al. Reductions in all-cause, cancer, and coronary mortality in statin-treated patients with heterozygous familial hypercholesterolaemia: A prospective registry study. Eur Heart J. 2008; 29: 2625-2633.
18. Ito MK, McGowan MP, Moriaty PM; National Lipid Association Expert Panel on Familial Hypercholesterolemia. Management of familial hyperlipidemias in adult patients. recommendations from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5 (3 Suppl): S38-S45.
19. Leren TP, Finborud TH, Manshaus TE, et al. Diagnosis of familial hypercholesterolemia in general practice using clinical diagnostic criteria or genetic testing as part of cascade genetic screening. Community Genet. 2008; 11: 26-35.
20. Hegele RA. Genetic susceptibility to heart disease in Canada: Lessons from patients with familial hypercholesterolemia. Genome. 2006; 49: 1343-1350.
21. Goldberg AC, Hopkins PN, Toth PP, et al. Familial hypercholesterolemia: Screening, diagnosis and management of pediatric and adult patients: Clinical guidance from the National Lipid Association Expert Panel on Familial Hypercholesterolemia. J Clin Lipidol. 2011; 5 (3 Suppl): S1-S8.
22. Nicholls P, Young I, Lyttle K, Graham C. Screening for familial hypercholesterolaemia. Early identification and treatment of patients is important. BMJ. 2001; 322: 1062.
23. Civeira F, Ros E, Jarauta E, et al. Comparison of genetic versus clinical diagnosis in familial hypercholesterolemia. Am J Cardiol. 2008; 102: 1187-1193.
24. Datta BN, McDowell IF, Rees A. Integrating provision of specialist lipid services with cascade testing for familial hypercholesterolaemia. Curr Opin Lipidol. 2010; 21: 366-371.
25. Defesche JC. Defining the challenges of FH screening for familial hypercholesterolemia. J Clin Lipidol. 2010; 4: 338-341.
26. Kusters DM, Homsma SJ, Hutten BA, et al. Dilemmas in treatment of women with familial hypercholesterolaemia during pregnancy. Neth J Med. 2010; 68: 299-303.
27. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med. 2012; 366: 1108-1118.
28. Giugliano RP, Desai NR, Kohli P, et al.; LAPLACE-TIMI 57 Investigators. Efficacy, safety, and tolerability of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 in combination with a statin in patients with hypercholesterolaemia (LAPLACE-TIMI 57): A randomised, placebo-controlled, dose-ranging, phase 2 study. Lancet. 2012; 380: 2007-2017.
29. Raal F, Scott R, Somaratne R, et al. Low-density lipoprotein cholesterol-lowering effects of AMG 145, a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease in patients with heterozygous familial hypercholesterolemia the Reduction of LDL-C With PCSK9 Inhibition in Heterozygous Familial Hypercholesterolemia Disorder (RUTHERFORD) randomized trial. Circulation. 2012; 126: 2408-2417.
30. McKenney JM, Koren MJ, Kereiakes DJ, et al. Safety and efficacy of a monoclonal antibody to proprotein convertase subtilisin/kexin type 9 serine protease, SAR236 553/REGN727, in patients with primary hypercholesterolemia receiving ongoing stable atorvastatin therapy. J Am Coll Cardiol. 2012; 59: 2344-2353.
31. Stein EA, Gipe D, Bergeron J, et al. Effect of a monoclonal antibody to PCSK9, REGN727/SAR236 553, to reduce low-density lipoprotein cholesterol in patients with heterozygous familial hypercholesterolaemia on stable statin dose with or without ezetimibe therapy: A phase 2 randomised controlled trial. Lancet. 2012; 380: 29-36.
32. Sullivan D, Olsson AG, Scott R, et al. Effect of a monoclonal antibody to PCSK9 on low-density lipoprotein cholesterol levels in statin-intolerant patients: The GAUSS randomized trial. JAMA. 2012; 308: 2497-2506.